The Role of sGC Stimulators and Activators in Heart Failure With Reduced Ejection Fraction

1. Virani, SS, Alonso, A, Benjamin, EJ, et al. Heart Disease and Stroke Statistics-2020 update: a report from the American Heart Association. Circulation. 2020;141(9):e139–e596.
Google Scholar | Crossref | Medline2. Packer, M, Anker, SD, Butler, J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424.
Google Scholar | Crossref | Medline3. Emdin, M, Aimo, A, Castiglione, V, et al. Targeting cyclic guanosine monophosphate to treat heart failure: JACC review topic of the week. J Am Coll Cardiol. 2020;76(15):1795–1807.
Google Scholar | Crossref | Medline4. Armstrong, PW, Lam, CSP, Anstrom, KJ, et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: the VITALITY-HFpEF randomized clinical trial. JAMA. 2020;324(15):1512–1521.
Google Scholar | Crossref | Medline5. Mitrovic, V, Jovanovic, A, Lehinant, S. Soluble guanylate cyclase modulators in heart failure. Curr Heart Fail Rep. 2011;8(1):38–44.
Google Scholar | Crossref | Medline6. Zhao, Y, Vanhoutte, PM, Leung, SWS. Vascular nitric oxide: beyond eNOS. J Pharmacol Sci. 2015;129(2):83–94.
Google Scholar | Crossref | Medline7. Murad, F . Shattuck lecture. Nitric oxide and cyclic GMP in cell signaling and drug development. N Engl J Med. 2006;355(19):2003–2011.
Google Scholar | Crossref | Medline8. Hofmann, F, Feil, R, Kleppisch, T, Schlossmann, J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev. 2006;86(1):1–23.
Google Scholar | Crossref | Medline | ISI9. Mohan, P, Brutsaert, DL, Paulus, WJ, Sys, SU. Myocardial contractile response to nitric oxide and cGMP. Circulation. 1996;93(6):1223–1229.
Google Scholar | Crossref | Medline10. Kojda, G, Kottenberg, K, Nix, P, Schlüter, KD, Piper, HM, Noack, E. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res. 1996;78(1):91–101.
Google Scholar | Crossref | Medline11. Buys, ES, Sips, P, Vermeersch, P, et al. Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice. Cardiovasc Res. 2008;79(1):179–186.
Google Scholar | Crossref | Medline12. Fraccarollo, D, Galuppo, P, Motschenbacher, S, Ruetten, H, Schäfer, A, Bauersachs, J. Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition. Basic Res Cardiol. 2014;109(4):421.
Google Scholar | Crossref | Medline13. Paulus, WJ, Vantrimpont, PJ, Shah, AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation. 1994;89(5):2070–2078.
Google Scholar | Crossref | Medline | ISI14. Follmann, M, Ackerstaff, J, Redlich, G, et al. Discovery of the soluble guanylate cyclase stimulator vericiguat (BAY 1021189) for the treatment of chronic heart failure. J Med Chem. 2017;60(12):5146–5161.
Google Scholar | Crossref | Medline15. Hofmann, F, Bernhard, D, Lukowski, R, Weinmeister, P. cGMP regulated protein kinases (cGK). In: Schmidt, HHHW, Hofmann, F, Stasch, J-P, eds. cGMP: Generators, Effectors and Therapeutic Implications. Springer Berlin Heidelberg; 2009:137–162.
Google Scholar | Crossref16. Madamanchi, NR, Vendrov, A, Runge, MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25(1):29–38.
Google Scholar | Crossref | Medline | ISI17. Münzel, T, Gori, T, Bruno, RM, Taddei, S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J. 2010;31(22):2741–2748.
Google Scholar | Crossref | Medline18. Follmann, M, Griebenow, N, Hahn, MG, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl. 2013;52(36):9442–9462.
Google Scholar | Crossref | Medline | ISI19. Evgenov, OV, Pacher, P, Schmidt, PM, Haskó, G, Schmidt, HHHW, Stasch, J-P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov. 2006;5(9):755–768.
Google Scholar | Crossref | Medline | ISI20. Weber, M, Lauer, N, Mülsch, A, Kojda, G. The effect of peroxynitrite on the catalytic activity of soluble guanylyl cyclase. Free Radic Biol Med. 2001;31(11):1360–1367.
Google Scholar | Crossref | Medline21. Agnoletti, L, Curello, S, Bachetti, T, et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic: role of tumor necrosis factor-alpha. Circulation. 1999;100(19):1983–1991.
Google Scholar | Crossref | Medline | ISI22. Maxwell, AJ, Schauble, E, Bernstein, D, Cooke, JP. Limb blood flow during exercise is dependent on nitric oxide. Circulation. 1998;98(4):369–374.
Google Scholar | Crossref | Medline23. Gheorghiade, M, Marti, CN, Sabbah, HN, et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail Rev. 2013;18(2):123–134.
Google Scholar | Crossref | Medline24. Laufs, U, Wassmann, S, Czech, T, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005;25(4):809–814.
Google Scholar | Crossref | Medline25. Suvorava, T, Lauer, N, Kojda, G. Physical inactivity causes endothelial dysfunction in healthy young mice. J Am Coll Cardiol. 2004;44(6):1320–1327.
Google Scholar | Crossref | Medline26. Fischer, D, Rossa, S, Landmesser, U, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J. 2005;26(1):65–69.
Google Scholar | Crossref | Medline27. Alem, MM . Endothelial dysfunction in chronic heart failure: assessment, findings, significance, and potential therapeutic targets. Int J Mol Sci. 2019;20(13):3198. doi:10.3390/ijms20133198
Google Scholar | Crossref28. Incalza, MA, D’Oria, R, Natalicchio, A, Perrini, S, Laviola, L, Giorgino, F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul Pharmacol. 2018;100:1–19.
Google Scholar | Crossref | Medline29. Taylor, AL, Ziesche, S, Yancy, C, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351(20):2049–2057.
Google Scholar | Crossref | Medline | ISI30. Daiber, A, Mülsch, A, Hink, U, et al. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol. 2005;96(7B):25i–36i.
Google Scholar | Crossref | Medline31. De Vecchis, R, Cesaro, A, Ariano, C, et al. Phosphodiesterase-5 inhibitors improve clinical outcomes, exercise capacity and pulmonary hemodynamics in patients with heart failure with reduced left ventricular ejection fraction: a meta-analysis. J Clin Med Res. 2017;9(6):488–498.
Google Scholar | Crossref | Medline32. Schmidt, HHHW, Schmidt, PM, Stasch, J-P. NO- and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol. 2009;(191):309–339.
Google Scholar | Crossref | Medline33. Stasch, J-P, Hobbs, AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009;(191):277–308.
Google Scholar | Crossref | Medline34. Gheorghiade, M, Greene, SJ, Filippatos, G, et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur J Heart Fail. 2012;14(9):1056–1066. doi:10.1093/eurjhf/hfs093
Google Scholar | Crossref | Medline35. Bonderman, D, Ghio, S, Felix, SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128(5):502–511.
Google Scholar | Crossref | Medline | ISI36. Gheorghiade, M, Greene, SJ, Butler, J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA. 2015;314(21):2251–2262.
Google Scholar | Crossref | Medline37. Lapp, H, Mitrovic, V, Franz, N, et al. Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. 2009;119(21):2781–2788.
Google Scholar | Crossref | Medline38. Pieske, B, Butler, J, Filippatos, G, et al. Rationale and design of the SOluble guanylate cyclase stimulatoR in heArT failurE studies (SOCRATES). Eur J Heart Fail. 2014;16(9):1026–1038.
Google Scholar | Crossref | Medline39. Armstrong, PW, Pieske, B, Anstrom, KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893.
Google Scholar | Crossref | Medline40. Armstrong, PW, Roessig, L, Patel, MJ, et al. A multicenter, randomized, double-blind, placebo-controlled trial of the efficacy and safety of the oral soluble guanylate cyclase stimulator: the VICTORIA trial. JACC: Heart Fail. 2018;6(2):96–104.
Google Scholar | Crossref | Medline41. McMurray, JJV, Solomon, SD, Inzucchi, SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Google Scholar | Crossref | Medline42. McMurray, JJV, Packer, M, Desai, AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
Google Scholar | Crossref | Medline | ISI43. Ezekowitz, JA, O’Connor, CM, Troughton, RW, et al. N-terminal Pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020;8(11):931–939.
Google Scholar | Crossref | Medline44. Maddox, TM, Januzzi, JL, Allen, LA, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772–810.
Google Scholar | Crossref | Medline45. Verquvo (Vericiguat) [Prescribing Information]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp. January 2021.
Google Scholar46. Greene, SJ, Butler, J, Albert, NM, et al. Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol. 2018;72(4):351–366.
Google Scholar | Crossref | Medline47. Teerlink, JR, Diaz, R, Felker, GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. 2021;384(2):105–116.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif